Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
(FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | -1.18%2.68B | 2.77%693.7M | -2.19%667.6M | -2.66%660.48M | -2.61%657.86M | 2.97%2.71B | -1.61%675.02M | 1.03%682.54M | 4.06%678.5M | 8.99%675.52M |
Operating revenue | -1.18%2.68B | 2.77%693.7M | -2.19%667.6M | -2.66%660.48M | -2.61%657.86M | 2.97%2.71B | -1.61%675.02M | 1.03%682.54M | 4.06%678.5M | 8.99%675.52M |
Cost of revenue | -5.04%581.73M | 5.43%152.13M | 0.38%150.34M | -8.42%141.27M | -16.01%137.99M | -8.38%612.62M | -16.18%144.3M | -15.65%149.77M | -7.09%154.25M | 7.44%164.3M |
Gross profit | -0.05%2.1B | 2.04%541.57M | -2.91%517.26M | -0.96%519.21M | 1.69%519.87M | 6.83%2.1B | 3.27%530.73M | 6.98%532.77M | 7.87%524.25M | 9.50%511.21M |
Operating expense | -46.33%528.27M | -44.47%132.67M | -49.65%123.6M | -48.39%126.56M | -42.88%145.45M | 1.53%984.25M | -5.80%238.92M | 2.43%245.5M | 2.31%245.2M | 7.69%254.62M |
Selling and administrative expenses | -3.43%258.76M | 0.11%67.6M | -7.30%60.09M | -1.59%62.38M | -4.86%68.7M | 2.32%267.94M | -4.37%67.52M | -1.55%64.82M | 0.17%63.38M | 16.23%72.21M |
Depreciation amortization depletion | -62.37%269.52M | -62.03%65.07M | -64.85%63.52M | -64.70%64.18M | -57.93%76.75M | 1.23%716.31M | -6.36%171.4M | 3.94%180.67M | 3.08%181.82M | 4.64%182.42M |
-Depreciation and amortization | -62.37%269.52M | -62.03%65.07M | -64.85%63.52M | -64.70%64.18M | -57.93%76.75M | 1.23%716.31M | -6.36%171.4M | 3.94%180.67M | 3.08%181.82M | 4.64%182.42M |
Operating profit | 40.81%1.57B | 40.13%408.9M | 37.03%393.65M | 40.71%392.65M | 45.92%374.42M | 11.99%1.11B | 12.11%291.8M | 11.19%287.28M | 13.28%279.05M | 11.37%256.59M |
Net non-operating interest income expense | 7.18%-406.74M | 3.84%-100.35M | 5.57%-101.09M | 6.11%-102.5M | 12.61%-102.81M | -6.99%-438.21M | 8.14%-104.36M | -6.43%-107.05M | -9.99%-109.17M | -22.34%-117.64M |
Non-operating interest income | 129.24%41.96M | 271.90%20.6M | 32.91%7M | 50.46%7.05M | 159.73%7.31M | 80.65%18.31M | 70.20%5.54M | 84.25%5.27M | 208.70%4.68M | 12.55%2.82M |
Non-operating interest expense | -2.02%427.44M | 9.87%115.09M | -4.03%102.9M | -3.86%104.61M | -9.21%104.83M | 9.09%436.24M | -6.29%104.75M | 8.86%107.22M | 13.52%108.81M | 23.13%115.47M |
Total other finance cost | 4.89%21.27M | 13.92%5.86M | 1.73%5.19M | -2.22%4.93M | 6.03%5.29M | 2.21%20.27M | 1.32%5.14M | 2.87%5.1M | 2.48%5.04M | 2.19%4.99M |
Other net income (expense) | -204.85%-390.23M | -211.44%-152.68M | 106.48%5.64M | -5,012.19%-143.04M | -2,059.40%-100.15M | -113.57%-128.01M | -174.52%-49.02M | -57.81%-87.01M | 103.57%2.91M | -94.59%5.11M |
Special income (charges) | 26.82%-139.81M | 65.81%-28.08M | 53.31%-18.06M | -0.96%-38.18M | -71.03%-55.49M | -171.37%-191.06M | -215.07%-82.12M | -151.53%-38.68M | -146.38%-37.82M | -138.30%-32.45M |
-Less:Restructuring and merger&acquisition | 19.73%25.95M | 30.07%6.57M | -3.99%5.39M | 32.73%6.57M | 22.45%7.42M | -19.16%21.67M | -37.13%5.05M | -18.00%5.61M | -27.47%4.95M | 18.67%6.06M |
-Less:Impairment of capital assets | -41.05%89.3M | -79.23%15.09M | -67.17%9.62M | 2.85%25.93M | 59.16%38.65M | 253.69%151.48M | 312.74%72.66M | 256.08%29.3M | 192.58%25.21M | 189.81%24.29M |
-Less:Other special charges | --5.94M | --1.51M | ---- | ---- | --4.43M | ---- | ---- | ---- | ---- | ---- |
-Write off | 4.02%18.63M | 11.20%4.9M | -19.00%3.05M | -25.81%5.68M | 137.36%4.99M | 5,309.67%17.91M | 49,088.89%4.41M | 1,135.41%3.77M | 8,073.96%7.66M | 1,493.94%2.1M |
Other non- operating income (expenses) | -497.15%-250.42M | -476.54%-124.6M | 149.04%23.7M | -357.44%-104.86M | -218.89%-44.65M | 502.40%63.05M | 303.32%33.09M | -21.57%-48.33M | 161.58%40.73M | -65.28%37.56M |
Income before tax | 40.87%772.67M | 12.61%155.87M | 219.89%298.21M | -14.86%147.12M | 19.03%171.47M | 4.31%548.5M | 7.45%138.42M | -9.18%93.22M | 163.45%172.79M | -37.03%144.06M |
Income tax | -53.04%23.99M | -179.31%-22.92M | 438.30%42.32M | 57.72%-12.34M | -61.09%16.93M | -22.65%51.09M | 10.09%28.9M | 172.67%7.86M | -718.92%-29.18M | 7.49%43.51M |
Net income | 50.51%748.68M | 63.24%178.79M | 199.77%255.89M | -21.05%159.45M | 53.69%154.54M | 8.18%497.42M | 6.78%109.53M | -14.43%85.36M | 192.07%201.97M | -46.60%100.55M |
Net income continuous Operations | 50.51%748.68M | 63.24%178.79M | 199.77%255.89M | -21.05%159.45M | 53.69%154.54M | 8.18%497.42M | 6.78%109.53M | -14.43%85.36M | 192.07%201.97M | -46.60%100.55M |
Minority interest income | 80.46%-859K | 5.16M | -28.49%-2.64M | -101.31%-3.38M | 0 | -169.75%-4.4M | 0 | -732.79%-2.06M | -359.73%-1.68M | -109.15%-663K |
Net income attributable to the parent company | 49.37%749.54M | 58.53%173.63M | 195.74%258.53M | -20.04%162.83M | 52.68%154.54M | 8.75%501.81M | 6.05%109.53M | -12.59%87.42M | 192.95%203.65M | -46.34%101.22M |
Preferred stock dividends | ||||||||||
Other preferred stock dividends | ||||||||||
Net income attributable to common stockholders | 49.37%749.54M | 58.53%173.63M | 195.74%258.53M | -20.04%162.83M | 52.68%154.54M | 8.75%501.81M | 6.05%109.53M | -12.59%87.42M | 192.95%203.65M | -46.34%101.22M |
Basic earnings per share | 50.00%6.96 | 59.41%1.61 | 197.53%2.41 | -19.15%1.52 | 52.13%1.43 | 8.67%4.64 | 5.21%1.01 | -12.90%0.81 | 193.75%1.88 | -46.29%0.94 |
Diluted earnings per share | 50.54%6.94 | 59.41%1.61 | 200.00%2.4 | -19.25%1.51 | 52.69%1.42 | 9.24%4.61 | 7.45%1.01 | -12.09%0.8 | 192.19%1.87 | -45.93%0.93 |
Dividend per share | 15.29%3.92 | 15.29%0.98 | 15.29%0.98 | 15.29%0.98 | 15.29%0.98 | 19.72%3.4 | 19.72%0.85 | 19.72%0.85 | 19.72%0.85 | 19.72%0.85 |
Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
Audit Opinions | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- |